Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2007;50:531-536
Published online before print July 16, 2007, doi: 10.1161/HYPERTENSIONAHA.107.091348
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
50/3/531    most recent
HYPERTENSIONAHA.107.091348v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ito, T.
Right arrow Articles by Ozawa, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ito, T.
Right arrow Articles by Ozawa, K.
Related Collections
Right arrow Gene expression
Right arrow Physiological and pathological control of gene expression
Right arrow Pulmonary biology and circulation
Right arrow Pulmonary circulation and disease
Right arrow Other Treatment
Right arrow Gene therapy

(Hypertension. 2007;50:531.)
© 2007 American Heart Association, Inc.


Original Articles

Adenoassociated Virus–Mediated Prostacyclin Synthase Expression Prevents Pulmonary Arterial Hypertension in Rats

Takayuki Ito; Takashi Okada; Jun Mimuro; Hiroshi Miyashita; Ryosuke Uchibori; Masashi Urabe; Hiroaki Mizukami; Akihiro Kume; Masafumi Takahashi; Uichi Ikeda; Yoichi Sakata; Kazuyuki Shimada; Keiya Ozawa

From the Divisions of Genetic Therapeutics (T.I., R.U., M.U., H.M., A.K., K.O.), Cardiovascular Medicine (T.I., H.M., K.S.), and Cell and Molecular Medicine (J.M.,Y.S.), Jichi Medical University, Tochigi, Japan; the Department of Molecular Therapy (T.O.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; and the Department of Organ Regeneration (M.T., U.I.), Shinshu University Graduate School of Medicine, Matsumoto, Japan.

Correspondence to Takayuki Ito or Keiya Ozawa, Division of Genetic Therapeutics, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan. E-mail titou{at}jichi.ac.jp or kozawa@jichi.ac.jp

Prostacyclin synthase (PGIS) is the final committed enzyme in the metabolic pathway of prostacyclin production. The therapeutic option of intravenous prostacyclin infusion in patients with pulmonary arterial hypertension is limited by the short half-life of the drug and life-threatening catheter-related complications. To develop a better delivery system for prostacyclin, we examined the feasibility of intramuscular injection of an adenoassociated virus (AAV) vector expressing PGIS for preventing monocrotaline-induced pulmonary arterial hypertension in rats. We developed an AAV serotype 1–based vector carrying a human PGIS gene (AAV-PGIS). AAV-PGIS or the control AAV vector expressing enhanced green fluorescent protein was injected into the anterior tibial muscles of 3-week–old male Wistar rats; this was followed by the monocrotaline administration at 7 weeks. Eight weeks after injecting the vector, the plasma levels of 6-keto-prostaglandin F1{alpha} increased in a vector dose-dependent manner. At this time point, the PGIS transduction (1x1010 genome copies per body) significantly decreased mean pulmonary arterial pressure (33.9±2.4 versus 46.1±3.0 mm Hg; P<0.05), pulmonary vascular resistance (0.26±0.03 versus 0.41±0.03 mm Hg · mL–1 · min–1· kg–1; P<0.05), and medial thickness of the peripheral pulmonary artery (14.6±1.5% versus 23.5±0.5%; P<0.01) as compared with the controls. Furthermore, the PGIS-transduced rats demonstrated significantly improved survival rates as compared with the controls (100% versus 50%; P<0.05) at 8 weeks postmonocrotaline administration. An intramuscular injection of AAV-PGIS prevents monocrotaline-pulmonary arterial hypertension in rats and provides a new therapeutic alternative for preventing pulmonary arterial hypertension in humans.


Key Words: hypertension • pulmonary • gene therapy • remodeling • prostacyclin synthase




This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K. R. Stenmark, B. Meyrick, N. Galie, W. J. Mooi, and I. F. McMurtry
Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure
Am J Physiol Lung Cell Mol Physiol, December 1, 2009; 297(6): L1013 - L1032.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Strassheim, S. R. Riddle, D. L. Burke, M. W. Geraci, and K. R. Stenmark
Prostacyclin Inhibits IFN-{gamma}-Stimulated Cytokine Expression by Reduced Recruitment of CBP/p300 to STAT1 in a SOCS-1-Independent Manner
J. Immunol., December 1, 2009; 183(11): 6981 - 6988.
[Abstract] [Full Text] [PDF]